What is Fauna Bio?
Fauna Bio operates at the vanguard of biotechnology, utilizing advanced genomic research to decode the biological mechanisms that protect animals from disease. By identifying these natural evolutionary adaptations, the company aims to translate these findings into novel human therapies. This approach positions Fauna Bio as a disruptive force in drug discovery, moving beyond traditional models to explore the vast, untapped potential of animal genomics. The company's research platform is designed to accelerate the identification of drug targets, effectively shortening the development lifecycle for complex medical treatments.
How much funding has Fauna Bio raised?
Fauna Bio has raised a total of $13.1M across 2 funding rounds:
Angel/Seed
$4.1M
Angel/Seed
$9M
Angel/Seed (2019): $4.1M, investors not publicly disclosed
Angel/Seed (2021): $9M led by Lifeforce Capital Gp I, True Ventures, and Boom Capital
Key Investors in Fauna Bio
Lifeforce Capital Gp I
A venture capital firm specializing in early-stage healthcare and software-driven life sciences companies.
True Ventures
A Silicon Valley-based venture capital firm that provides seed and series A financing to early-stage technology startups.
Boom Capital
An investment firm focused on supporting high-growth companies within the deep tech and biotechnology sectors.
What's next for Fauna Bio?
With this major enterprise-level funding, Fauna Bio is well-positioned to scale its proprietary research infrastructure and expand its clinical pipeline. The strategic allocation of this capital will likely focus on enhancing computational biology capabilities and deepening partnerships within the pharmaceutical ecosystem. As the company transitions from early-stage research to more robust development phases, the focus will shift toward validating these genomic insights in human clinical settings, potentially setting a new standard for precision medicine and therapeutic efficacy.
See full Fauna Bio company page
